Additional studies will evaluate the effectiveness of the pill in glioblastoma, a lethal brain tumor, small-cell lung cancer and prostate cancer.

CNN: Drug shows promise in leukemia and intestinal cancer

On April 28 Dendreon of Seattle notched Food and Drug Administration approval for Provenge, its cell therapy designed to train the immune system to fight prostate cancer.

FORBES